Document Detail

Alteration of myocardial metaiodobenzylguanidine uptake after treatment of phaeochromocytoma and neuroblastoma.
MedLine Citation:
PMID:  10853814     Owner:  NLM     Status:  MEDLINE    
The relationships between changes in myocardial uptake of metaiodobenzylguanidine (MIBG) and those in circulating catecholamines and cardiac function after treatment of phaeochromocytoma and neuroblastoma were evaluated. Iodine-123 or iodine-131 MIBG scintigraphy was performed before and after surgical resection and/or chemotherapy for primary tumours in nine patients with phaeochromocytoma and 13 patients with neuroblastoma. Changes in myocardial MIBG uptake after treatment were estimated by the heart-to-upper mediastinum (H/M) uptake ratios on the images obtained 24 h after MIBG injection, which were compared with serum levels of noradrenaline (NA) and adrenaline (A). Cardiac function was assessed by echocardiography, with measurements of the left ventricular ejection fraction (LVEF). Before treatment, eight patients with phaeochromocytoma and three with neuroblastoma showed poor myocardial MIBG uptake, with highly elevated circulating NA and A. Echocardiography, however, did not show cardiac dysfunction in these patients with the exception of two patients with phaeochromocytoma. With normalization of NA and A levels after treatment, all of these patients except for the two with persistent cardiac dysfunction showed restoration of myocardial MIBG uptake. The H/M ratios increased significantly after treatment in both patient groups, i.e. with phaeochromocytoma and with neuroblastoma (P<0.0001 and P<0.05, respectively), and these ratios correlated inversely with circulating NA and A before and after treatment. By contrast, there was no significant correlation between H/M ratios and LVEF in these two groups. These results indicate that suppression of myocardial MIBG uptake usually may not be related to cardiac dysfunction and may be reversible following normalization of excess catecholamine levels after treatment in patients with neuroadrenergic tumours. However, the suppression may persist in the presence of catecholamine-induced cardiac dysfunction. The assessment of myocardial MIBG uptake can be a helpful adjunct in monitoring the normalization of circulating catecholamine levels and also in identifying the presence of cardiac dysfunction in treated patients with neuroadrenergic tumours.
K Suga; N Ogasawara; M Ariga; K Motoyama; A Hara; N Kume; N Matsunaga
Related Documents :
7465844 - Thallium-201 myocardial redistribution imaging 24 hours following stress exercise.
18371594 - Analysis of apical remodeling in gated myocardial perfusion spect imaging in ischemic c...
16569554 - Determining myocardial viability in chronic ischemic left ventricular dysfunction: a pr...
3490374 - Dynamic 123i-hda myocardial scintigraphy after aortocoronary bypass grafting.
15226704 - Delta creatine kinase-mb outperforms myoglobin at two hours during the emergency depart...
22240124 - Hypothermia therapy neurological and cardiac benefits.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  European journal of nuclear medicine     Volume:  27     ISSN:  0340-6997     ISO Abbreviation:  Eur J Nucl Med     Publication Date:  2000 May 
Date Detail:
Created Date:  2000-09-19     Completed Date:  2000-09-19     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7606882     Medline TA:  Eur J Nucl Med     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  574-82     Citation Subset:  IM    
Department of Radiology, Yamaguchi University School of Medicine, Ube, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
3-Iodobenzylguanidine / diagnostic use,  pharmacokinetics*
Adrenal Gland Neoplasms / metabolism*,  radionuclide imaging,  therapy
Aged, 80 and over
Catecholamines / blood,  urine
Child, Preschool
Heart / radionuclide imaging
Middle Aged
Myocardium / metabolism*
Neuroblastoma / metabolism*,  radionuclide imaging,  therapy
Pheochromocytoma / metabolism*,  radionuclide imaging,  therapy
Radiopharmaceuticals / diagnostic use,  pharmacokinetics*
Reg. No./Substance:
0/Catecholamines; 0/Radiopharmaceuticals; 77679-27-7/3-Iodobenzylguanidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is...
Next Document:  Radiation dose rates from patients undergoing PET: implications for technologists and waiting areas.